170 related articles for article (PubMed ID: 33215275)
1. Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells.
Wei W; Li H; Zhang G; Zhang Y; Wu K; Bao R; Wang G; Zheng H; Xia Y; Li C
Med Oncol; 2020 Nov; 37(12):116. PubMed ID: 33215275
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells.
Zhang Y; Liu Q; Wei W; Zhang G; Yan S; Dai R; Sun Y; Su D; Lv S; Xia Y; Li J; Li C
BMC Cancer; 2021 Oct; 21(1):1101. PubMed ID: 34645397
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.
Li C; Sun H; Wei W; Liu Q; Wang Y; Zhang Y; Lian F; Liu F; Li C; Ying K; Huo H; Qi Z; Li B
Cell Oncol (Dordr); 2020 Dec; 43(6):1099-1116. PubMed ID: 32710433
[TBL] [Abstract][Full Text] [Related]
4. EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism.
Modernelli A; Naponelli V; Giovanna Troglio M; Bonacini M; Ramazzina I; Bettuzzi S; Rizzi F
Sci Rep; 2015 Oct; 5():15270. PubMed ID: 26471237
[TBL] [Abstract][Full Text] [Related]
5. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition induces both pro- and anti-cell death pathways in prostate cancer cells.
Yang W; Monroe J; Zhang Y; George D; Bremer E; Li H
Cancer Lett; 2006 Nov; 243(2):217-27. PubMed ID: 16413676
[TBL] [Abstract][Full Text] [Related]
7. Proteasome Inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) Enhances Therapeutic Effect of Paclitaxel on Breast Cancer by Inhibiting Nuclear Factor (NF)-κB Signaling.
Zhang Y; Yang B; Zhao J; Li X; Zhang L; Zhai Z
Med Sci Monit; 2018 Jan; 24():294-304. PubMed ID: 29332931
[TBL] [Abstract][Full Text] [Related]
8. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
Golden EB; Lam PY; Kardosh A; Gaffney KJ; Cadenas E; Louie SG; Petasis NA; Chen TC; Schönthal AH
Blood; 2009 Jun; 113(23):5927-37. PubMed ID: 19190249
[TBL] [Abstract][Full Text] [Related]
9. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
Gulla A; Morelli E; Johnstone M; Turi M; Samur MK; Botta C; Cifric S; Folino P; Vinaixa D; Barello F; Clericuzio C; Favasuli VK; Maisano D; Talluri S; Prabhala R; Bianchi G; Fulciniti M; Wen K; Kurata K; Liu J; Penailillo J; Bragoni A; Sapino A; Richardson PG; Chauhan D; Carrasco RD; Hideshima T; Munshi NC; Anderson KC
Blood; 2024 Jun; 143(25):2612-2626. PubMed ID: 38551812
[TBL] [Abstract][Full Text] [Related]
10. PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance.
Fu Z; Lu C; Zhang C; Qiao B
Anticancer Drugs; 2019 Aug; 30(7):e0773. PubMed ID: 30807553
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis.
Chandra A; Wang L; Young T; Zhong L; Tseng WJ; Levine MA; Cengel K; Liu XS; Zhang Y; Pignolo RJ; Qin L
FASEB J; 2018 Jan; 32(1):52-62. PubMed ID: 28860152
[TBL] [Abstract][Full Text] [Related]
12. Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.
Cacan E; Spring AM; Kumari A; Greer SF; Garnett-Benson C
Int J Mol Sci; 2015 Dec; 16(12):30405-21. PubMed ID: 26703577
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling.
Waad Sadiq Z; Brioli A; Al-Abdulla R; Çetin G; Schütt J; Murua Escobar H; Krüger E; Ebstein F
Front Immunol; 2023; 14():982720. PubMed ID: 36936919
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
Thapa RK; Nguyen HT; Jeong JH; Shin BS; Ku SK; Choi HG; Yong CS; Kim JO
Nanomedicine; 2017 Apr; 13(3):885-896. PubMed ID: 27993720
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent.
Miles MA; Harris MA; Hawkins CJ
Apoptosis; 2019 Jun; 24(5-6):404-413. PubMed ID: 30997620
[TBL] [Abstract][Full Text] [Related]
16. Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
Leshchenko VV; Kuo PY; Jiang Z; Weniger MA; Overbey J; Dunleavy K; Wilson WH; Wiestner A; Parekh S
Oncotarget; 2015 Sep; 6(29):27332-42. PubMed ID: 25714012
[TBL] [Abstract][Full Text] [Related]
17. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
18. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
19. Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells.
Li Y; Dong S; Tamaskar A; Wang H; Zhao J; Ma H; Zhao Y
Oncol Res; 2020 Dec; 28(5):497-507. PubMed ID: 32580819
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab.
Wang D; Xu Q; Yuan Q; Jia M; Niu H; Liu X; Zhang J; Young CY; Yuan H
Oncogene; 2019 May; 38(18):3458-3474. PubMed ID: 30647455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
